Response of Diabetic Papillopathy to Intravitreal Bevacizumab
Diabetic papillopathy is an uncommon hyperemic optic disc swelling that occurs in patients with long-standing diabetes, is typically self-resolving with minimal effect on vision, and is likely ischemic in origin. The purpose of the current report is to document the response of diabetic papillopathy...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162739/ https://www.ncbi.nlm.nih.gov/pubmed/21887082 http://dx.doi.org/10.4103/0974-9233.84056 |
_version_ | 1782210859382079488 |
---|---|
author | Al-Dhibi, Hassan Khan, Arif O. |
author_facet | Al-Dhibi, Hassan Khan, Arif O. |
author_sort | Al-Dhibi, Hassan |
collection | PubMed |
description | Diabetic papillopathy is an uncommon hyperemic optic disc swelling that occurs in patients with long-standing diabetes, is typically self-resolving with minimal effect on vision, and is likely ischemic in origin. The purpose of the current report is to document the response of diabetic papillopathy to intravitreal injection of bevacizumab (Avastin, Genentech Inc, San Francisco, California, USA), a humanized monoclonal antibody to vascular endothelial growth factor. |
format | Online Article Text |
id | pubmed-3162739 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Medknow Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-31627392011-09-01 Response of Diabetic Papillopathy to Intravitreal Bevacizumab Al-Dhibi, Hassan Khan, Arif O. Middle East Afr J Ophthalmol Case Report Diabetic papillopathy is an uncommon hyperemic optic disc swelling that occurs in patients with long-standing diabetes, is typically self-resolving with minimal effect on vision, and is likely ischemic in origin. The purpose of the current report is to document the response of diabetic papillopathy to intravitreal injection of bevacizumab (Avastin, Genentech Inc, San Francisco, California, USA), a humanized monoclonal antibody to vascular endothelial growth factor. Medknow Publications 2011 /pmc/articles/PMC3162739/ /pubmed/21887082 http://dx.doi.org/10.4103/0974-9233.84056 Text en Copyright: © Middle East African Journal of Ophthalmology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Al-Dhibi, Hassan Khan, Arif O. Response of Diabetic Papillopathy to Intravitreal Bevacizumab |
title | Response of Diabetic Papillopathy to Intravitreal Bevacizumab |
title_full | Response of Diabetic Papillopathy to Intravitreal Bevacizumab |
title_fullStr | Response of Diabetic Papillopathy to Intravitreal Bevacizumab |
title_full_unstemmed | Response of Diabetic Papillopathy to Intravitreal Bevacizumab |
title_short | Response of Diabetic Papillopathy to Intravitreal Bevacizumab |
title_sort | response of diabetic papillopathy to intravitreal bevacizumab |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162739/ https://www.ncbi.nlm.nih.gov/pubmed/21887082 http://dx.doi.org/10.4103/0974-9233.84056 |
work_keys_str_mv | AT aldhibihassan responseofdiabeticpapillopathytointravitrealbevacizumab AT khanarifo responseofdiabeticpapillopathytointravitrealbevacizumab |